TUBVP and HOLEP: desirable surgical options for large benign prostatic hyperplasia ( >80 ml).
- Author:
Qing-yi ZHU
1
;
Xiao-jian GU
;
Lin YUAN
;
Wei-zhou HUANG
;
Li ZHANG
;
Zi-jie LU
;
Ping ZHANG
;
Jian SU
;
Yan XU
;
Yang ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Humans; Lasers, Solid-State; therapeutic use; Male; Prostate; pathology; Prostatic Hyperplasia; pathology; surgery; Retrospective Studies; Transurethral Resection of Prostate; methods
- From: National Journal of Andrology 2008;14(10):907-910
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the safety and efficacy of the two surgical alternatives, transurethral bipolar vaporization resection of the prostate (TUBVP) and holmium laser enucleation of the prostate (HOLEP), in the treatment of large benign prostatic hyperplasia (BPH).
METHODSRetrospective analyses were made of 56 cases of large BPH ( >80 ml), 34 treated by TUBVP with the Bipolar Vaporization System (ACMI Medical Ltd, U.K.) at 160 W in cutting and 80 W in coagulation mode, and 22 by HOLEP with the Holmium Laser System (LUMNIS Ltd, US) at 100W. The safety and efficacy of the two approaches were assessed based on the operative and follow-up data.
RESULTSBlood loss was significantly less in the HOLEP than in the TUBVP group ( P < 0.01), but the time of postoperative bladder irrigation and catheter indwelling was obviously shorter in the latter. IPSS, Qmax and Residual unine were markedly improved at 1 and 3 months after the surgery, with no statistically significant differences between the two groups.
CONCLUSIONBoth TUBVP and HOLEP are safe and effective surgical options for the treatment of large BPH. Particularly the former, easier to be popularly applied, is promising to be a new "gold standard" in the surgical treatment of BPH.
